Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The prostacyclin receptor (IP), encoded by the PTGIR gene, is a G protein-coupled receptor that binds prostacyclin (prostaglandin I2 or PGI2). Activation of the IP receptor leads to vasodilation, inhibition of platelet aggregation, and moderation of vascular smooth muscle cell function, contributing to cardioprotection. It is a therapeutic target for pulmonary arterial hypertension and other diseases involving vasoconstriction or thrombosis. Dysfunction or reduced signaling can increase cardiovascular risk.
Agonists bind to the IP receptor, activating Gs proteins, stimulating adenylate cyclase, increasing intracellular cAMP levels, and leading to downstream effects mediated by PKA and Epac.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostacyclin Receptor (IP).